Fulranumab
As of the edition of 20 October 2026, Fulranumab is an antibody: went quiet in 2016; acts on NGF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2016
- Kind
- Antibody
- Registered trials
- 13, 6 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Fulranumab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NGF | Beta-nerve growth factor | P01138 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 1 | 0 | 6 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials | 2005 to now |
| Johnson & Johnson | Lead sponsor of trials | 2009 to now |